Sagespring Wealth Partners
GTBP icon

Sagespring Wealth Partners’s GT Biopharma GTBP Stock Holding History

Sagespring Wealth Partners’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.8K Buy
+800
New +$8.11K ﹤0.01% 846

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Everhart Financial Group
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $479M AUM 15.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Sagespring Wealth Partners's GTBP Position: Q2 2026 in Review

Sagespring Wealth Partners opened a new position in GT Biopharma (GTBP) in Q2 2026: 800 shares worth $9.8K. The stake represents ﹤0.01% of the portfolio and ranks #846 among its holdings.

55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Sagespring Wealth Partners held 800 shares of GT Biopharma worth $9.8K as of Q2 2026.
  • GT Biopharma was a new Sagespring Wealth Partners position in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Sagespring Wealth Partners's portfolio in Q2 2026, its #846 holding.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Sagespring Wealth Partners's 13F filing for Q2 2026, filed 3 Aug 2026.